Cencora, Inc. (NYSE:COR) Position Increased by Mizuho Securities USA LLC

Mizuho Securities USA LLC grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 46.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,621 shares of the company's stock after buying an additional 5,309 shares during the period. Mizuho Securities USA LLC's holdings in Cencora were worth $3,734,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in COR. Whittier Trust Co. increased its stake in Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC boosted its position in Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after purchasing an additional 46 shares during the period. WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. JFS Wealth Advisors LLC raised its position in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. lifted its stake in shares of Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after purchasing an additional 47 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Cencora Stock Performance

COR traded up $2.94 during trading hours on Thursday, hitting $274.33. The company's stock had a trading volume of 1,015,455 shares, compared to its average volume of 1,379,449. The firm has a market capitalization of $53.20 billion, a PE ratio of 39.02, a PEG ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $274.80. The company has a 50-day simple moving average of $252.47 and a 200 day simple moving average of $240.68.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. Cencora's dividend payout ratio (DPR) is 31.29%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on COR shares. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares of the company's stock, valued at $3,934,326.20. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock valued at $8,034,778 in the last quarter. Insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.